Publicaciones científicas
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Jatin Shah 1 , Sharon Shacham 1 , Michael Kauffman 1 , Patrick Daniele 2 , Dimitrios Tomaras 2 , Gabriel Tremblay 2 , Rene-Olivier Casasnovas 3 , Marie Maerevoet 4 , Josee Zijlstra 5 , George Follows 6 , Joost S P Vermaat 7 , Nagesh Kalakonda 8 , Andre Henri Goy 9 , Sylvain Choquet 10 , Eric Van Den Neste 11 , Brian T Hill 12 , Catherine Thieblemont 13 , Federica Cavallo 14 , Fátima de la Cruz 15 , John Kuruvilla 16 , Nada Hamad 17 , Reda Bouabdallah 18 , Ulrich Jäger 19 , Paolo Caimi 20 , Ronit Gurion 21 , Krzysztof Warzocha 22 , Sameer Bakhshi 23 , Juan Manuel Sancho 24 , Michael Schuster 25 , Miklós Egyed 26 , Fritz Offner 27 , Theodoros P Vasilakopoulos 28 , Priyanka Samal 29 , Agnes Nagy 30 , Matthew Ku 31 , Miguel Ángel Canales Albendea 32
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma.
Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models.
Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001).
Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.
CITA DEL ARTÍCULO Future Oncol. 2021 Apr;17(11):1295-1310. doi: 10.2217/fon-2020-0946. Epub 2021 Feb 2.
Nuestros autores
